OWNERSHIP RIGHTS OVER BIOHYBRID ROBOTIC ENTITIES

1. INTRODUCTION

Biohybrid robotic entities combine living biological components, such as cells, tissues, or microorganisms, with engineered mechanical structures, sensors, actuators, and control systems. They may be developed for medical research, environmental monitoring, drug testing, or other scientific applications. Their hybrid nature creates difficult legal questions concerning ownership, intellectual property, biological materials, licensing, and liability.

In India, no separate statute comprehensively defines ownership rights over biohybrid robotic entities. Their legal status must therefore be assessed under existing property law, the Patents Act, 1970, the Copyright Act, 1957, applicable biomedical research rules, and biological-resource legislation. Ownership of the physical device does not automatically confer unrestricted rights over its biological components or every invention incorporated into it.

2. LEGAL FRAMEWORK

A. OWNERSHIP OF THE PHYSICAL ENTITY

A biohybrid robot may qualify as movable property where the applicable legal requirements are satisfied. Ownership may arise through lawful manufacture, purchase, transfer, or other recognised legal arrangements. Contracts should identify who owns the assembled entity, replacement components, biological materials, experimental data, and improvements.

B. INTELLECTUAL PROPERTY RIGHTS

The Patents Act, 1970, governs patent protection for qualifying inventions. Novelty, inventive step, industrial applicability, and statutory exclusions must be considered. Section 3(j) excludes plants and animals in whole or in part, other than microorganisms, and essentially biological processes for producing or propagating plants and animals. The precise treatment of engineered biological components depends on the claims and relevant judicial interpretation.

Copyright may protect qualifying software, technical documentation, and original expressive works, but it does not automatically confer ownership of the physical robot or biological material.

C. BIOLOGICAL MATERIAL AND ETHICAL RESTRICTIONS

Human cells, tissues, and other biological materials raise questions of consent, privacy, research ethics, and permissible use. Ownership of a machine does not automatically authorise the unrestricted use of human-derived material. Research involving human biological material must comply with applicable legal and ethical requirements.

The Biological Diversity Act, 2002, as amended, may also apply where Indian biological resources are accessed or used. Applicable access, intellectual-property, and benefit-sharing requirements depend on the persons involved and the nature of the activity.

3. IMPORTANT CASE LAWS

1. BTS Research International Pty Ltd v. Controller General of Patents & Designs (Calcutta High Court, 2025) — DIRECT ANALOGOUS AUTHORITY

The Court considered patentability issues concerning artificially generated tri-hybrid cells under Section 3(j) of the Patents Act. The decision is relevant to biohybrid technology because it examines the significance of artificial technical intervention in creating biological material. It concerns patent eligibility, not ownership of an assembled biohybrid robot.

2. Diamond v. Chakrabarty (1980) — DIRECT ANALOGOUS PATENT AUTHORITY

The United States Supreme Court held that a genetically engineered bacterium could qualify as patentable subject matter under US patent law. The decision illustrates how engineered biological inventions may receive intellectual-property protection under the applicable legal framework. It does not establish ownership rights over every living component of a biohybrid system.

3. Moore v. Regents of the University of California (1990) — ANALOGOUS BIOLOGICAL-MATERIAL AUTHORITY

The California Supreme Court rejected a conversion claim concerning a patient's excised cells used in research but allowed other claims relating to disclosure and fiduciary duties to proceed. The decision illustrates the distinction between ownership of biological material and rights arising from informed consent or misuse. It is a foreign decision and does not determine Indian law.

4. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) — ANALOGOUS PATENT AUTHORITY

The United States Supreme Court held that naturally occurring DNA is not patentable merely because it has been isolated, while qualifying synthetically created complementary DNA may be patentable. The decision demonstrates that technical innovation does not automatically establish exclusive rights over biological material as it exists in nature.

5. R v. Kelly (1998) — ANALOGOUS PROPERTY AUTHORITY

The English Court of Appeal considered whether preserved human body parts could constitute property for purposes of criminal law where work or skill had given them attributes beyond their natural state. The decision is relevant to debates about processed biological material but does not create a general ownership rule for human tissues or biohybrid robots.

6. Thaler v. Comptroller-General of Patents, Designs and Trade Marks (UK Supreme Court, 2023) — ANALOGOUS INVENTORSHIP AUTHORITY

The UK Supreme Court held that an artificial intelligence system could not be named as an inventor under the applicable patent legislation. Although the case did not concern biohybrid robots, it illustrates the importance of statutory rules governing inventorship and the allocation of intellectual-property rights. It does not independently determine who owns a biohybrid entity.

4. PRACTICAL OWNERSHIP AND COMPLIANCE REQUIREMENTS

Organisations developing biohybrid robots should:

Document ownership of the assembled device and its replaceable components.

Identify inventors and establish valid intellectual-property assignments.

Specify ownership and permitted use of biological materials through lawful agreements and consent procedures.

Verify patent eligibility and any applicable biological-resource approvals.

Establish rules for data access, maintenance, modification, transfer, and commercialisation.

Allocate responsibility for biological contamination, malfunction, and injury through appropriate contracts and insurance.

5. CONCLUSION

Ownership rights over biohybrid robotic entities require separate analysis of physical property, intellectual property, biological materials, and regulatory obligations. Indian law provides relevant principles through property, patent, copyright, biodiversity, and biomedical research frameworks, but does not establish a distinct legal personality for biohybrid robots. The cited cases offer guidance on engineered biological inventions, human-derived materials, and inventorship; none directly determines ownership of a complete biohybrid robotic entity. Clear legislation, precise contractual arrangements, and responsible research governance remain essential.